FZD2 and glioma: Further analysis of cancer and adjacent normal tissues using the GTEx database revealed significant differences in FZD2 expression in GBM, lower-grade glioma (LGG), lung adenocarcinoma (LUAD), testicular germ cell tumors (TGCT), skin cutaneous melanoma (SKCM), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), and other cancers.